Pioneer in digital therapeutics and biotechnology, accelerating the development and commercialization of innovative medicines.
Roivant Sciences leverages technology, data analytics, and specialized subsidiary teams (termed 'Vants') to expedite the discovery, development, and commercialization of transformative therapies across multiple therapeutic areas. It integrates digital health tools and novel business models in biotech, seeking to address inefficiencies in healthcare and deliver value to both patients and providers.
competitors.competitorDetail.metrics.missionStatement
To rapidly develop transformative medicines that address significant unmet medical needs using innovative science and technology-driven entrepreneurship.
competitors.competitorDetail.metrics.visionStatement
To revolutionize drug development and digital therapeutics for a healthier future, maximizing impact across healthcare worldwide.
competitors.competitorDetail.metrics.foundedYear
2014
competitors.competitorDetail.metrics.ceo
Matthew Gline
competitors.competitorDetail.metrics.employees
900+
competitors.competitorDetail.metrics.revenue
$500M+ (estimated, 2023)
competitors.competitorDetail.metrics.headquarters
33 Irving Place, New York, NY 10003, USA
competitors.competitorDetail.metrics.marketShare
Emerging leader in digital therapeutics and innovative biotech development.
competitors.competitorDetail.metrics.usp
Multi-venture platform integrating AI, data science, and operational agility to bring innovations to healthcare markets faster than traditional pharma.
competitors.competitorDetail.metrics.pricingModel
Value-based and/or subscription models for digital therapy; traditional pharma pricing for biotech assets
- VantAI (AI-driven drug discovery)
- Dermavant (dermatology)
- Urovant (urology)
- Immunovant (autoimmune)
- Arbutus Biopharma (hepatitis B therapeutics, significant stake)
- Python (AI, data analytics)
- Cloud computing (AWS, Google Cloud)
- Custom SaaS platform for clinical trial data
- Secure patient data management
competitors.competitorDetail.metrics.marketPositioning
Agile innovator bridging biotech and digital health, with capabilities spanning molecule to digital solution.
- Biopharma partners
- Healthcare providers
- Payers seeking digital therapy solutions
- Patients with chronic and underserved health conditions
- Direct partnerships with healthcare providers
- Pharma co-development deals
- Digital therapeutics delivered via healthcare systems
- Licensing and out-licensing
- Thought leadership in digital health events
- Collaboration with patient advocacy groups
- Medical journal publications
- Investor relations and conference presence
- Pharma and provider outreach
- Sumitomo Pharma (Strategic Commercial Partnership)
- Pfizer (R&D Collaboration)
- Silicon Therapeutics (Acquisition (for computational discovery))
- AI-powered drug discovery and analytics
- Digital therapeutics for CNS and chronic diseases
- Flexible biotech subsidiary model ('Vants')
- Rapid asset in-licensing and development platform
- Collaborative R&D partnerships
- Robust pipeline of novel therapies across multiple diseases
- Innovative use of data science and AI for drug discovery
- Agile 'Vant' structure for rapid asset commercialization
- Strong partnerships with top pharmaceutical and biotech firms
- Dependency on regulatory approvals for revenue growth
- High R&D costs and capital intensity
- Some pipeline projects have failed in late-stage trials
- Expansion into more digital and connected therapeutics
- Strategic acquisitions of underdeveloped assets
- Deepening AI integration for personalized medicine
- Intense competition from large pharma and digital health startups
- Regulatory and reimbursement shifts in global health policy
- Clinical trial risks and patent expirations
competitors.competitorDetail.metrics.growthRateYOY
30%+ (platform expansion and new Vant launches)
competitors.competitorDetail.metrics.profitMargin
Not consistently positive (reflects high reinvestment in R&D)
competitors.competitorDetail.metrics.customerAcquisitionCost
Not publicly disclosed (pharma/B2B + provider-centric sales)
competitors.competitorDetail.metrics.customerLifetimeValue
High (driven by value of long-term therapies and digital solutions)
competitors.competitorDetail.metrics.churnRate
Low – pharma/biotech model, sticky partnerships
| competitors.competitorDetail.metrics.fundingStage | competitors.competitorDetail.metrics.fundingAmount | competitors.competitorDetail.metrics.fundingDate |
|---|---|---|
| Series A | $100M | 2015-05-20 |
| Series B | $500M | 2017-08-07 |
| IPO (SPAC merger) | $611M | 2021-09-30 |
- Entrepreneurial subsidiary ('Vant') culture
- Cross-disciplinary teams
- Rapid innovation adoption
- Focus on patient impact
- Diversity and inclusion initiatives
- Fierce Biotech Fierce 15 (2023) - Fierce Biotech
- Top 100 Innovators in Biotech (2022) - CB Insights
- Best Places to Work in Biotech (2023) - BioSpace
| competitors.competitorDetail.news.title | competitors.competitorDetail.news.publishedOn | competitors.competitorDetail.news.readMore |
|---|---|---|
| Roivant’s Immunovant announces positive results in autoimmune disease | 2023-10-18 | Endpoints News |
| Roivant enters strategic collaboration with Roche on AI-driven drug discovery | 2024-04-09 | BioCentury |